治療途徑抗發炎藥市場 - 技術，適應症，市場與預測

Therapeutic Pathway Anti-Inflammatory Drugs & Markets, Technology, Indications, Markets & Forecasts

出版日期: 2025年03月31日 | 出版商:

Greystone Research Associates | 英文 129 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

本市場研究報告對推動藥物傳輸領域這一不斷增長的技術、產品和市場參與者進行了全面的評估和分析。本報告旨在讓製藥決策者、藥物開發商和配方師、藥物設備設計師和產業策略家詳細了解吸入式中樞神經系統治療對製藥策略和醫療保健治療方案日益增長的影響。它對於醫療保健組織的業務經理、醫療保健管理人員和投資者也將很有用。

多種驅動因子

向中樞神經系統注射藥物面臨獨特的挑戰。然而，藥物開發商和研究人員發現，透過吸入方式輸送中樞神經系統藥物可以緩解其中的一些問題。鼻腔通路和血管系統為將小分子藥物和生物製劑穿過血腦屏障輸送到中樞神經系統提供了一個有吸引力的途徑。深肺給藥可能具有良好的藥物動力學特性。與口服藥物相比，吸入給藥還可以提供更快的起效速度，且所需的給藥頻率更低。這些潛在的益處促進了針對多種疾病的吸入式中樞神經系統藥物的開發。隨著人口老化和管理式醫療計劃促使家庭醫療保健和藥物自我管理的擴大，吸入藥物越來越被視為對患者友好且具有成本效益的藥物。我們的分析表明，透過吸入進行中樞神經系統輸送非常適合利用這些趨勢，並發展成為未來藥物開發和中樞神經系統治療商業化的關鍵組成部分。

IL-23/IL-17 軸作為自體免疫的治療標靶 IL-23/IL-17 軸在人類自體免疫疾病中變得重要，從而促使新型治療藥物的批准和快速開發。針對各種細胞激素或細胞激素受體的單株抗體以及針對 RORyt 和 JAK 的小分子抑制劑正在改變治療格局，目前已有三十多種不同的產品獲得批准或處於臨床開發階段。針對 IL-17 和 IL-17RA 的人源化單株抗體能夠改善中度至重度乾癬和乾癬關節炎的治療效果。

您將學到什麼

哪些吸入藥物以粉末形式提供，它們如何分發，有哪些設備，以及誰在分發它們？
哪些吸入乾粉藥物處於後期開發階段，誰在開發這些藥物，以及用於哪些適應症？
推動吸入乾粉藥物/設備需求的關鍵因素有哪些？
目前的市場規模是多少，誰是市佔率領先者，以及他們在 2024 年的市佔率將會是多少？
藥品開發商和設備製造商之間的關係有多重要？該行業的主要聯盟有哪些？
乾粉吸入產品的關鍵設計因素、技術和市場發展挑戰是什麼？
影響乾粉吸入器市場的關鍵經濟、技術和監管因素有哪些？

調查方法：

該研究方法以對主要市場參與者、技術開發商、分銷商、行業專家和市場影響者（包括監管機構、行業協會和材料標準機構）進行深入訪談的形式進行初步研究。

根據行業期刊文章、技術文獻、行業出版物、公司數據表和公開聲明以及政府機構和行業協會的統計數據等二手資料來源對主要資訊進行評估和標準化。

使用標準建模和統計技術可以估計和預測市場需求和未來市場活動。

摘要整理
Th17途徑
針對 Th17 發炎路徑級聯
白細胞介素 6 (IL-6)
已核准的藥物
正在研發的藥物
白血球介素 IL-6R
已核准的藥物
正在研發的藥物
Janus激酶/酪胺酸激酶抑制劑
已核准的藥物
正在研發的藥物
訊號蛋白
訊號傳導和轉錄活化因子 (STATs)
白血球介素-21 (IL-21)
白血球介素-21受體 (IL-21R)
白血球介素-23 (IL-23)
已核准的藥物
正在研發的藥物
白血球介素-23受體 (IL-23R)
白血球介素-17A (IL-17A)
已核准的藥物
白血球介素-17C (IL-17C)
正在研發的藥物
白血球介素 17A/17F
正在研發的藥物
白介素-17RA (IL-17RA)
已核准的藥物
轉化生長因子-β RI/RII (TGF-β RI/RII)
正在研發的藥物
視黃酸相關孤兒受體RORyt
正在研發的藥物
白細胞介素17
正在研發的藥物
白細胞介素-22（IL-22）
市場狀況
市場規模
競爭情勢
Th17 路徑介導的發炎性疾病
最大可尋址市場規模
競爭情勢
市場參與企業的簡介

簡介目錄

This new market study, "Therapeutic Pathway Anti-Inflammatory Drugs & Markets" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of inhaled CNS therapies on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Converging Factors Driving

Delivering drugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicated that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.

The IL-23/IL-17 axis as a therapeutic target in autoimmunity The identification of the IL-23/IL-17 axis as critical for human autoimmune disease has led to the approval and rapid development of novel therapeutic agents. Monoclonal antibodies to a variety of cytokines and cytokine receptors and small-molecule inhibitors of RORyt and JAKs are changing the therapeutic landscape, with three dozen distinct products now approved or in clinical development. Humanized monoclonal antibodies to both IL-17 and IL-17RA are enabling improved outcomes for moderate to severe psoriasis as well as psoriatic arthritis.

What You Will Learn:

What inhalable drugs are supplied in powder form, how are they marketed, what are the device specifics, and who markets them?
What inhalable dry powder drugs are in late stage development, who are the developers, and what indications are they targeting?
What are the major factors driving inhaled dry powder drug/device demand?
What is the size of the market today, who are the market share leaders, and what will the market share be in 2024?
How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
What are the essential design factors, technologies and market development issues for dry powder inhalation products?
What are the significant economic, technology, and regulatory factors affecting the market for dry powder inhalers?

Methodology:

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.